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Abstract
Nucleotide excision repair, a DNA repair mechanism, is the major repair
pathway responsible for removal of platinum-based anticancer drugs. In this
study, 146 bp duplexes were prepared containing either a site-specific cis-
diammineplatinum(Il)-DNA intrastrand d(GpG) cross-link or a cis-
diamminephenanthridinechloroplatinum(Il)-DNA dG adduct. Comparison of
the repair efficiencies of the two adducts reveals that the
diamminephenanthridinechloroplatinum(lI)-DNA dG lesion eludes the
nucleotide excision repair pathway better than diammineplatinum(lI)-DNA
intrastrand d(GpG) cross-link. A factor that may be relevant to the difference
is the influence of platination on DNA-mediated charge transfer. Atomic force
microscopy is a method by which we can explore the possibility that
phenanthriplatin influences charge transfer properties of DNA. Long DNA
duplexes site-specifically modified with cisplatin or phenthanriplatin were
prepared for AFM studies.
Thesis supervisor: Stephen J. Lippard
Title: Arthur Amos Noyes Professor of Chemistry
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Chapter 1.
Comparison of Nucleotide Excision Repair Efficiency between
Cisplatin and Phenanthriplatin Modified DNA
7
INTRODUCTION
Cisplatin, cis-diamminedichloroplatinum(lI) was approved for clinical use
in 1978 and remains one of the most effective and widely used anticancer
drugs. It is used to treat a variety of human cancers including testicular,
ovarian, and non-small cell lung cancers. 3 Cisplatin is worthy of the title 'the
penicillin of cancer' but it still leaves something to be desired as there are a
number of negative side-effects associated with its administration, including
nephrotoxicity, emetogenesis, and neurotoxicity.4 Acquired and inherent
resistance to the drug must also be considered.5 To overcome these
limitations, thousands of cisplatin analogues have been synthesized and
tested for anticancer activity. Among all these complexes, only carboplatin
(cis-diammine(1,1'-cyclobutanedicarboxylato)platinum(lI)) and oxaliplatin
((trans-L-diaminocyclohexane)oxalatoplatinum(lI)) (Figure 1.1), have been
approved by the FDA for the treatment of cancer.4
0 
H2//0
H3N Ci H3N O O
3N""N 0' 0
0
Cisplatin Carboplatin Oxaliplatin
Figure 1.1. Chemical structures of FDA-approved platinum anticancer agents.
The mechanism of how platinum(II) anticancer drugs work has been
studied extensively. Taking cisplatin as an example, the N7 positions of
guanine bases in DNA form covalent bonds to the platinum atom after the
drug has been activated by losing two chloride ligands.7 The major products
are 1,2-intrastrand and 1,3-intrastrand adducts comprising 50%-90% and
10%-25%, respectively, of the total adducts formed by cisplatin.6,8 The DNA
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damage leads to transcription inhibition, which is believed to contribute to the
cytotoxicity of cisplatin.9' 10 After becoming a road block on DNA, the platinum
lesion is either removed by nucleotide excision repair (NER) or apoptosis is
triggered, the latter of which is the goal in platinum-based chemotherapy."' 12
Based on the study of cisplatin, various compounds with non-classical
structures have been designed in order to make new drugs that have fewer
side effects or lower resistance than conventional platinum based agents.
Among them, monofunctional platinum complexes caught researchers'
attention by displaying an impressive antitumour spectrum and activites
different from those of current platinum drugs.13 Rather than forming DNA
crosslinks, these compounds attack the N7 positions of guanine residues to
form monofunctional platinum-DNA lesions, which significantly inhibit
transcription, both in vitro and in live cells. Among the new monofunctional
platinum compounds, cis-diamminephenanthridinechloroplatinum( II) nitrate
(phenanthriplatin) (Figure 1.2) shows significant antitumor potential and is
seven to forty times more cytotoxic than cisplatin in cancer cells from different
origins. /
CN NH,
Pt
C1 NH)
Figure 1.2. Structure of phenanthriplatin.
To date, compared with bifunctional anticancer agents, little work has
been done to explain the mechanism of monofunctional platinum complexes.
Previous research has shown that, when attached to the N7 position of a
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guanine residue in DNA, monofunctional platinum compounds distort the DNA
helix less than bifunctional platinum compunds do, allowing monofunctional
lesions to elude the nucleotide excision repair pathway.13 A direct NER study
of phenanthriplatin has not previously been carried out, so in this thesis we
studied the nucleotide excision repair efficiency of a phenanthriplatin
platinated DNA duplex compared with that of a cisplatin platinated one.
EXPERIMENTAL PROCEDURES
Materials. Cisplatin was obtained from Strem Chemicals.
Phosphoramidites and other reagents for DNA synthesis were obtained from
Glen Research. All enzymes and enzyme buffers were purchased from New
England Biolabs unless otherwise noted. All other reagents and solvents
were purchased from commercial sources and used without further
purification. DNA syntheses were performed on an Applied Biosystems Model
392 DNA/RNA Synthesizer at a 1.0 pmole scale. Radioactive gels were
visualized using a Storm 840 phosphorimager and sample radioactivity was
quantitated with a Beckman LS 6500 scintillation counter. HPLC was
performed using an Agilent 1100 series system. Atomic absorption
spectroscopy was performed on a Perkin-Elmer AAnalyst 600 system. UV-VIS
spectra were obtained on a HP 8453 UV-visible spectrometer. Protein
purifications were performed on a Biorad system having an automated
fraction collector. Cell free extract from CHO AA8 cells was obtained from
Joyce Reardon in Sancar lab at the University of North Carolina.
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Synthesis, Purification, and Characterization of Oligonucleotides. To make
platination site-specific on DNA, the target 146 bp DNA duplex was divided
into several short strands that were synthesized separately. The final
platinated 146 bp duplex was prepared by annealing and ligating five short
strands (see Figure 1.3 for complete sequences). The cisplatin platination site
is on the 14-mer and phenanthriplatin platination is on the 16-mer. The
strategy for synthesizing a site-specifically platinated DNA probe is shown in
Figure 1.4.
63-mer: 5'-ATC AAT ATC CAC CTG CAG ATT CTA CCA AAA GTG TAT TTG
GAA ACT GCT CCA TCA AAA GGC ATG
14-mer: 5'-TTC ACC GGA ATT CC
69-mer: 5'-CCT CAA CAT CGG AAA ACT ACC TCG TCA AAG GTT TAT
GTG AAA ACC ATC TTA GAC GTC CAC CTA TAA CTA
86-mer: 5'-ATG TTG AGG GGA ATT CCG GTG AAC ATG CCT TTT GAT
GGA GCA GTT TCC AAA TAC ACT TTT GGT AGA ATC TGC
AGG TGG ATA TTG AT
60-mer: 5'-TAG TTA TAG GTG GAC GTC TAA GAT GGT TTT CAC ATA
AAC CTT TGA CGA GGT AGT TTT CCG
(A)
61-mer: 5'-ATC AAT ATC CAC CTG CAG ATT CTA CCA AAA GTG TAT TTG
GAA ACT GCT CCA TCA AAA GGC A
16-mer: 5'-CCT CCT CGT CTC TTC C
69-mer: 5'-CCT CAA CAT CGG AAA ACT ACC TCG TCA AAG GTT TAT
GTG AAA ACC ATC TTA GAC GTC CAC CTA TAA CTA
86-mer: 5'-ATG TTG AGG GGA AGA GAC GAG GAG GTG CCT TTT GAT
GGA GCA GTT TCC AAA TAC ACT TTT GGT AGA ATC TGC
AGG TGG ATA TTG AT
60-mer: 5'-TAG TTA TAG GTG GAC GTC TAA GAT GGT TTT CAC ATA
AAC CTT TGA CGA GGT AGT TTT CCG
(B)
Figure 1.3. (A) Sequence of the five oligonucleotide starting materials for
constructing the cisplatin platinated 146 bp duplex. (B) Sequence of the five
oligonucleotide starting materials for constructing the phenanthriplatin
platinated 146 bp duplex.The platination sites are highlighted in bold.
11
Figure 1.4. Strategy for synthesizing a site-specifically platinated DNA probe.
For site-specifically cisplatin modified 146 bp, fragment I is 69-mer, fragment
11 is 14-mer, fragment Ill is 63-mer, fragment IV is 86-mer, and fragment V is
60-mer. For site-specifically phenanthriplatin modified 146 bp, fragment I is
69-mer, fragment |1 is 16-mer, fragment Ill is 61-mer, fragment IV is 86-mer,
and fragment V is 60-mer. The platination sites are highlighted with stars.
All oligonucleotides were synthesized with an Applied Biosystems DNA
synthesizer on a 1 pmol scale and purified by 6% denaturing PAGE, except
the 14-mer and 16-mer, which were purified by HPLC. To prepare the
cisplatin platinated 14-mer oligonucleotide, cisplatin was allowed to react with
AgNO3 (2.0 equiv) for 5 hours at room temperature in the dark. The AgCI
precipitate was removed by centrifugation. The 14-mer DNA was then
combined with 2 equiv of activated cisplatin in 10 mM sodium phosphate
buffer pH 6.8, and the solution was incubated at 37*C overnight. The product
was purified by ion exchange HPLC and characterized by UV spectroscopy,
atomic absorption spectroscopy (AAS), and nuclease S1 digestion. DNA
concentrations were determined by quantifying the UV absorption at 260 nm.
A purified phenanthriplatin platinated 16-mer was obtained from Dr. Ga Young
Park.
Preparation of Radio-Labeled Full-Length Site-Specifically Modified
Platinum-DNA Probes. Single stranded 14-mer oligonucleotides were 5'-end
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labeled with y-32P-ATP and T4 polynucleotide kinase. Single stranded 63-mer
and 60-mer DNAs were 5'-end labeled (phosphorylated) with cold ATP and T4
polynucleotide kinase. The three phosphorylated short DNA strands were
mixed with the other two, followed by ethanol precipitation. DNA pellets were
re-dissolved in 1 X annealing buffer (10 mM Tris, pH 7.5-8.0, 50 mM NaCl, 1
mM EDTA), heated to 90 0C for 3 min and slowly cooled down to room
temperature over 90 min. Subsequently, the annealed sample was treated
with DNA ligase (New England Biolabs) to afford radiolabeled 146-bp duplex.
Ligated DNA was ethanol precipitated and purified with 6% preparative
denaturing polyacrylamide gels. Gel pieces containing single stranded 146-
mers were excised with the aid of autoradiography and soaked in annealing
buffer to extract DNA from the gel. Radioabelled DNA was isolated as a dry
pellet by ethanol precipitation. Platinated duplexes were obtained by
reannealing (DNA single strands were heated at 90 0C for 3 min and cooled to
room temperature slowly over 3 hours) and characterized with 6% denaturing
and 5% native polyacrylamide gels. The final products were quantitated by
scintillation counting.
Nucleotide Excision Repair Assay. Both radiolabeled cisplatin and
phenanthriplatin modified DNA samples (5-20 fmol) were incubated with 60
pg of cell free extract from CHO AA8 cells, which was obtained from Joyce
Reardon in the Sancar lab, at 30 0C for 90 min in 25 pL of excision repair
buffer (32 mM HEPES-KOH, pH 7.9, 64 mM KCI, 6.4 mM MgCl2 , 0.24 mM
EDTA, 0.8 mM DTT, 2 mM ATP, 0.2 mg/mL BSA, 5.5% glycerol, 4.8%
sucrose). Then the reaction mixtures were treated with proteinase K, phenol-
chloroform extracted, and analyzed on an 8% denaturing PAGE gel. A
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phosphorimager and the ImageQuant system were used to measure the
levels of radioactivity in the bands arising from excised oligonucleotides (20-
30 nucleotides).
RESULTS AND DISCUSSION
Synthesis, Purification, and Characterization of Oligonucleotides. Highly
pure oligonucleotides were obtained by the methods described above. For
short (< 20 bp) oligos, leaving the DMT group on during synthesis and
purifying by reverse phase HPLC proved to be an easy way to separate the
desired product from failure sequences, because the hydrophobic DMT group
drastically increases the retention time on a C18 column. In a longer oligo
synthesis, the lack of 100% capping efficiency leads to a greater percentage
of strands being continued instead of acetylated. As a result, more products
will be synthesized that are missing nucleotides from the middle of the strand,
still having a DMT group attached at the end. These shorter sequences
cannot be sufficiently resolved from the desired product by HPLC. PAGE is a
more efficient method of separating oligos differing by only 1 nucleotide in
length; longer strands are therefore purified by gel electrophoresis. A
denaturing gel showing the purified 63-mer, 69-mer, 86-mer, and 60-mer DNA
strands is depicted in Figure 1.5 and yields of purified oligonucleotides are
shown in Table 1.1.
14
123 45
150-mer
100-mer -
75-mer
50-mer
25-mera
Figure 1.5. Characterization of purified oligonucleotides (see Figure 1.3): lane
1: DNA ladder; lane 2: 63-mer; lane 3: 69-mer; lane 4: 86-mer; lane 5: 60-mer.
Oligonucleotides Yield (%)
63-mer 44
69-mer 36
86-mer 35
60-mer 69
Table 1.1. Yields of four oligonucleotides
All DNA strands were synthesized on a
calculated based on UV-Vis absorption.
after denaturing PAGE purification.
1 pmol scale and the yields were
Platination of Short DNA Strands. The 14-mer was ordered from
Integrated DNA Technologies and purified by HPLC; the methods of
characterization are shown in Table 1.2 and purification results are given in
Figure 1.6.
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Column:
Column Temp:
Flow rate:
Detection:
Mobile Phase
Time (min): 0
DNAPac PA-100, 9 x 250 mm,
ambient
4.0 mL/min
UV, 260 nm
A: 25 mM Tris-HCI pH 7.4 5% acetonitrile
B: 25 mM Tris-HCI pH 7.4 5% acetonitrile 1M NaCl
15 118 19
%B 10 130 140 110 1
(A)
Column:
Column Temp:
Flow rate:
Detection:
Mobile Phase
DNAPac PA-100, 9 x 250 mm,
ambient
4.0 mL/min
UV, 260 nm
A: 25 mM Tris-HCI pH 7.4 5% acetonitrile
B: 25 mM Tris-HCI pH 7.4 5% acetonitrile 1M NaCl
Time (min): 0 15 117 120
%B 10 50 80 10
(B)
Table 1.2. (A). HPLC conditions for purification of crude 14-mer.
conditions for characterization of the purified 14-mer.
mAU
600
(A)
(B)
400
200
0
mAU
200
150.
100
50.
0-
0
U,
A~.
10
10 20 mir
CO
W
10 mir
Figure 1.6. (A). HPLC chromatogram of the purification of the 14-mer from
failure sequences. The peak at 16.315 min is the desired product; the failure
sequences elute earlier, between 4-13 min. (B). Characterization of the
purified 14-mer. Note: purified DNA in (A) shown different location with the
major peak in (B) was due to the different gradients (see Table 1.2).
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(B). HPLC
After treatment of the 14-mer with cisplatin, the platinated sample was
purified by HPLC; the purification methods are shown in Table 1.3 and
purification results are given in Figure 1.7.
Column:
Column Temp:
Flow rate:
Detection:
Mobile Phase
Time (min): 0
%B 15
DNAPac PA-1 00, 9 x 250 mm,
ambient
4.0 mL/min
UV, 260 nm
A: 25 mM Tris-HCI pH 7.4 5% acetonitrile
B: 25 mM Tris-HCI pH 7.4 5% acetonitrile 1M NaCl
3 11 11.5 12
37 42 15 15
Table 1.3. HPLC conditions
the reaction mixture.
mAU
200
150
100
50
0
0
for isolation of the cisplatin modified 14-mer from
Q
Li,
'1-
c~)
0)
U,
I-
If)
5 10
(A)
U,
U,
0
(g~
mAU
100
80
60
40
20
0
0 2 4 6
(B)
Figure 1.7. (A). HPLC chromatogram of the purification of cisplatin-14-mer.
Peak 2 (6.934 min) is the starting material; peak 1 (5.027 min) is the
platinated product. (B). Characterization of the purified cisplatin-14-mer.
The final product was tested by AA and UV-Vis spectroscopy and, as
indicated by the rb value (0.99 ± 0.01), the bound platinum to nucleotide ratio,
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the isolated product was a pure mono-platinated 14-mer. To analyze the
platinated 14-mer, S1 digestion was carried out and compared to results for
the original 14-mer. The unplatinated (2 nmol) and platinated (2 nmol) 14-mer
were incubated with 5 pL of S1 nuclease, separately, in 100 pL of enzyme
buffer (50 mM sodium acetate pH 4.5, 280 mM NaCl, 4.5 mM ZnSO 4) at 37 *C
overnight. Then 5 pL of 1.5 M Tris-HCI pH 8.8 and 1 pL calf intestinal
phosphatase were added and the mixture was incubated for another 4 h at 37
*C. After addition of 6 pL of 0.1 M HCI and centrifugation, both samples were
analyzed by HPLC. The results are given in Figure 1.8 and Table 1.4. The
shift of the band at the G positions in the platinated sample provides clear
evidence of the 1,2 GG-crosslink, because the platinum adduct occupies the
N7 positions and blocks the reaction.
C G
cn TM,4
10 120
(A)
CG
Pt-GG
A
10 20
Time/min
30 mir
Time/min
30 min
(B)
Figure 1.8. (A).
chromatogram of
HPLC chromatogram of digested 14-mer. (B). HPLC
digested platinated 14-mer.
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0
Abs/mAU
80
60
40
20
0
-20
Abs/mAU
40
30
20
10
0
0
Relative
response factor
Theoretical
value 14-mer Pt-14-mer
C 1.0 5 5.0 5.0
G 1.6 2 2.0 1.8
T 1.2 4 4.1 4.4
A 2.0 3 2.8 2.8
Table 1.4. Characterization of 14-mer and cisplatin platinated 14-mer by
nucleotide composition analysis. Relative response factors, which are due to
the differences in the extinction coefficient of C, G, T, and A bases, were
applied in calculations to integrate signals from different nucleobases.
Preparation of Radiolabeled Full-Length Site-Specifically Modified
Platinum-DNA Probes. Ligated cis-Pt-146 bp and phenanthri-Pt-146 bp DNA
duplexes were first purified by 6% denaturing gel electrophoresis to remove
unligated short DNA strands as shown in Figures 1.9 and 1.10. The isolated
samples were extracted from gel pieces and re-annealed followed by
characterization with 5% native PAGE as shown in Figure 1.11.
cis-Pt-146 ho 4 1 Product excised
Figure 1.9. Purification of ligated site-specifically cisplatin modified 146 bp
with 6% denaturing PAGE (70 V, 1800 W, 110 min).
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phenanthri-
Pt-146 bp
-+ Product excised
Figure 1.10. Purification of ligated site-specifically phenanthriplatin platinated
146 bp DNA with 6% denaturing PAGE.
1 2 3
200 k
150 bR
100kga
Figure 1.11. Native PAGE gel characterization of purified site-specifically
platinated 146 bp duplexes: lane 1: DNA ladder; lane 2: site-specifically
cisplatin platinated 146 bp; lane 3: site-specifically phenanthriplatin platinated
146 bp.
Restriction Enzyme Digestion of the Cisplatin Modified 146 bp. Platination
of the 146 bp duplex was checked by digestion with the restriction enzyme
20
-.. ,I
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EcoRi and comparison to digestion of the unplatinated 146 bp duplex. The
modified DNA duplex is cut completely by the enzyme, but the platinated DNA
duplex should not be cut at all. A 2.2% agarose gel run for the experiment, as
shown in Figure 1.12, reveals that the platination cross-link blocks digestion
(lane 5).
1 2 3 4 5 6
200 he
150 ka
100
75 4tw
Figure 1.12. Agarose gel result of restriction digestion of unplatinated and
cisplatin platinated 146 bp. Lane 1: DNA ladder; lane 2: unplatinated 146 bp;
lane 3: unplatinated 146 bp incubated with EcoRI; the restriction site is in the
middle of the duplex so the digestion products were -75-mers; lane 4: cisPt-
146 bp; lane 5: cisPt-146 bp incubated with EcoRI; Lane 6: DNA ladder.
Comparison of Nucleotide Excision Repair from Platinated 146 bp with
Cisplatin versus Phenanthriplatin. The substrates used in this study were
cisplatin and phenanthriplatin platinated 146 bp duplexes. After incubation
with repair proteins, the reaction products were analyzed with 8% denaturing
PAGE (Figure 1.13). Comparison of excision signals for cisplatin and
phenanthriplatin platinated DNA indicates that the efficiency of NER of site-
specifically cisplatin platinated DNA is 3-fold higher than that of site-
specifically phenanthriplatin platinated DNA.
21
1 2
Excision part
Figure 1.13. Excision assay with site-specifically platinated 146 bp duplexes.
Lane 1: site-specifically cisplatin platinated 146 bp; lane 2: site-specifically
phenanthriplatin platinated 146 bp.
SUMMARY AND CONCLUSION
Site-specifically platinated 146 bp duplexes were synthesized from
cisplatin and phenanthriplatin, purified, and characterized for use in a
nucleotide excision repair assay. The excision efficiency of the cisplatin
modified DNA is 2.45%, which is greater than that of the phenanthriplatin
modified sample, 0.52%. These results indicate that phenanthriplatin, a
monofunctional anticancer drug candidate, can elude the nucleotide excision
22
repair pathway better than cisplatin. Other pathways for repairing this lesion
remain to be investigated.
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Chapter 2.
Site-specifically Platinated Long DNA Strands from pCMV-
GLuc Plasmids for Atomic Force Microscopy (AFM) Studies
24
INTRODUCTION
Various platinum compounds with non-classical structures have been
designed in order to lower side effects or circumvent the resistance that arises
in treatment with conventional platinum based agents.16 Previous research
revealed that some monofunctional platinum complexes are able to lead to
apoptosis as well.17 The structure of modified DNA reveals that bending,
unwinding, and distortions of the double helix are critical determinants of
cisplatin cytotoxicity in vivo.4 Based on the monofunctional nature of
phenanthriplatin-dG lesions and the expected lack of canonical DNA
distortion, other factors such as its ability to stall RNA Pol 11 are likely to
account for its activity. Another factor that may be relevant is the influence of
platination on DNA-mediated charge transfer (CT). If the DNA contains a
mismatched base pair or lesion that distorts the structure of the DNA base
stack, charge transfer along the DNA strand will be cut off.18 In
electrochemical studies, this would be manifest as an attenuated signal
compared to control DNA.19
Atomic force microscopy (AFM) is another method by which we can
explore the possibility that phenanthriplatin influences charge transfer
properties of DNA. Briefly, AFM is used to ascertain whether proteins that are
able to send and receive charge redistribute onto strands of DNA that contain
damage. This redistribution would result from an inability of the proteins to
transfer charge through the DNA. When proteins collect around the damage,
signal traveling through DNA stops.20 AFM can be used to directly image the
distribution of proteins on the DNA strand and provide some clues as to the
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manner by which platinatum lesions are detected before excision. Long DNA
strands with and without site-specific platination and with a mismatched base
pair were prepared by the 'gapping' strategy, previously developed in the
Lippard lab. In addition to a strand containing the monofunctional drug
phenanthriplatin, DNA strands containing either a site-specific cisplatin lesion
or a mismatched base pair were also synthesized to be used as controls for
the AFM experiments carried out by the Barton group at Caltech.
Experimental Procedures
Materials. All chemical reagents were obtained from Sigma-Aldrich unless
otherwise stated. All enzymes and enzyme buffers were purchased from New
England Biolabs unless otherwise noted. DNA strands were bought from IDT
and DH5a cells were obtained from Invitrogen. DNA concentrations were
measured by UV/vis spectroscopy at 260 nm using a Varian Cary 1E-
spectrometer fitted with a microprobe and using an extinction coefficient of 50
pg/mL/OD. Agarose electrophoreses through gels (0.8-1.0% w/v) containing
0.5 pg/ml EtdBr were imaged using the BioRad Fluor-S Multilmager.
Vector Construction and Preparation. Gaussia luciferase expression
vectors for incorporation of site-specific cisplatin-dGG and phenanthriplatin-
dG lesions, pGLuc4temGG and pGLuc8temG, respectively, were prepared by
following protocols reported previously.
Preparation of Platinated Insertion Strand. A 16-mer oligonucleotide
containing a site-specific cis-{Pt(NH 3)2}2'-dGG lesion and a 16-mer
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oligonucleotide containing a site specific cis-{Pt(N H3)2(phen)} 2+-dG
(phen=phenanthridine) lesion were made and purified by Dr. Ga Young Park.
Preparation of Long DNA Duplexes (3,982 bp, 2,230 bp, and 1,752 bp)
from pGLuc Plasmids. Both pGLuc4temGG and pGLuc8temG plasmids were
transformed into DH5a cells on LB agar plates separately with 100 mg/L of
ampicillin. Colonies were randomly picked for larger scale inoculation. The
plasmids were purified with a Qiagen maxiprep kit. With purified plasmids in
hand, BstZ171 and Scal restriction enzymes were used to obtain 3,982 bp,
2,230 bp, and 1,752 bp duplexes as shown in Figure 2.1.
Scal Sit
1"161l 184
lio 5643 M l 243
P gI TShKI 21 2 9 Platination' k 4" ca. Site
pCFgr21 f c %M 4CM
57e O re s n i ae h R Modified pCMV-GLuc
8bJ1491,
strands 3 or8AFMstd3982 bp
9MIl 351 *
heftS 2368
9%MS 3278 'Uul 2384
"Il 3'1Q bfll 238' /
(s1 and Scal) 2438 BstZl7l'
PI-3h1111 2712
Pul 2W4
Figure 2.1. Left. Restriction map of pCMV-GLuc Vector from BioLabs Inc.
website. Only unique restriction sites are shown. Rigth. Modified pGLuc vector
with platination site and restriction sites related to preparation of long DNA
strands for AFM studies.
The plasmid was incubated with a four-fold excess of restriction enzymes
(BstZll7l and Scal) at 37 'C for 80 min. Following incubation, two
phenol/chloroform/isoamyl alcohol extractions were performed to remove the
enzymes. An 0.8% agarose gel was run at 112 V for 100 min to separate the
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DNA strands. Different bands were cut under UV light and separately put into
3,500 MWCO tubes with 5 mL of 1X TAE buffer. The tubing was sealed, and
a voltage of 150 V was applied to the sample for another 60 min to elute the
DNA from the gel resin into the buffer. The solution was concentrated and
precipitated with ethanol. The DNA pellets were dissolved in water, and the
DNA concentrations were measured by UVNis spectroscopy at 260 nm.
Sample purity was verified by 1.2% analytical agarose gel as shown in
Figures 2.2 and 2.3.
1 2 3 4
4k w
2k O
1.5k
Figure 2.2. Agarose gel characterization of long DNA strands from pGLuc
4temGG plasmid. Lane 1: 1kb DNA ladder; lane 2: 3982 bp from
pGLuc4temGG; lane 3: 2230 bp from pGLuc4temGG; lane 4: 1752 bp from
pGLuc4temGG.
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Figure 2.3. Agarose gel characterization of long DNA strands from pGLuc
8temG plasmid. (A) Lane 1: 1kb DNA ladder; lane 2: 3982 bp from
pGLuc8temG. (B) Lane 1: 1kb DNA ladder; lane 2: 2230 bp from
pGLuc8temG; lane 3: 1952 bp pGLuc8temG.
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Preparation of Site-Specifically Platinated Long DNA Duplexes from
pGLuc Plasmids. Site-specifically platinated pGLuc4temGG, 3,982 bp
containing a cis-{Pt(NH3)2}2+-dGG lesion between the CMV promoter and
luciferase expression gene, was prepared following the strategy published
previously21 as shown in Figure 2.4.
restriction site
5'
s, DNA duplex
nicking site nicking site
restriction site
5' nicked long
DAduplex
nicking site nicking site
complementary strand
re-annealing
V removed by diafiltration
restriction site
s1 gapped
s' DNA duplex
nicking site nicking site
re-annealing & ligation +S Pt insertion strand
restriction site
__________________________ platinated
s' DNA duplex
Figure 2.4. Overall scheme for preparing platinated DNA strands.
Briefly, a 90 pg quantity of pGLuc4temGG 3,982 bp was digested with 190
U Nt.BspQI at 37 0C for 1 h. The reaction mixture was heated at 80 *C for 20
min to deactivate the enzyme, followed by two phenol/chloroform/isoamyl
alcohol extractions to remove the enzyme. The mixture was ethanol
precipitated at -20 0C. The nicked plasmid was mixed with 1,000 equiv of
complementary DNA strand, 5'-TTTTGGAAGAGACGAGGAGGTTTT, in a
buffer of 10 mM Tris-HCI, 2 mM MgCl 2 , 0.4 M NaCl, pH 7.4, heated at 80 0C
for 5 min, and subsequently cooled at 4 *C over 4 hr. The gapped plasmid
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was purified by centrifugation through a 50 k MWCO ultrafiltration tube at
3,000 rpm, 4 *C for 30 min, and quantitated by UV-vis spectroscopy. A 55 pg
quantity of the gapped plasmid was annealed with 100 equiv of the insertion
strand in a buffer of 10 mM Tris-HCI, 2 mM MgC 2 , 0.4 M NaCl, pH 7.4 from
90 *C to 4 0C over 4 hr.
Restriction Analysis of Site-Specifically Platinated Plasmids. To carry out
a restriction analysis on ligated platinated or unplatinated plasmids, a 0.2 pg
quantity of pGLuc4temGG 3,982 bp, 2230 bp, and mismatched 3,982 were
incubated with 0.8 U PfIMI at 37 0C for 70 min. The DNA samples were
analyzed using 0.8% agarose gel electrophoresis. The gels containing 0.5
pg/mL ethidium bromide were analyzed with a BioRad Fluor-S Multilmager.
For pGLuc8temG DNA samples, BsmBI was used for restriction analysis.
Atomic Force Microscopy (AFM) Images (These experiments were carried
out by Pam Sontz in the Barton group). Three sets of samples were studied
with AFM. In the first set, 6 mM MgCl 2 and 100 ng of mismatched-long
strands 3982 bp with C:A mismatched were mixed with 100 ng of matched
short strands 2230 bp and the mixture was incubated in Tris-EDTA buffer
overnight at 4 0C, followed by incubation with 0.6 [tM portion of wild-type Endo
Ill overnight again. In the second set, 6 mM MgCl 2 and 100 ng of cisplatin
4temGG 3982 bp were mixed with 100 ng of matched control short strands
2230 bp and the mixture was incubated in Tris-EDTA buffer overnight at 4 0C,
followed by incubation with 0.6 [M portion of wild-type Endo Ill overnight
again. In the third set, 6 mM MgCl 2 and 100 ng of phenanthriplatin 8temG
3982 bp were mixed with 100 ng of matched control short strands 2230 bp
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and the mixture was incubated in Tris-EDTA buffer overnight at 4 00 followed
by incubation with 0.6 [tM portion of wild-type Endo Ill overnight again.
RESULTS AND DISCUSSION
Construction of pGLuc4temGG 3,982 bp and 2,230 bp Containing a Site-
Specific Cisplatin Lesion, pGLuc4temGG 3,982 bp Containing a Mismatched
Base Pair and pGLuc8temG 3,982 bp and 2,230 bp Containing Site-Specific
Phenanthriplatin Lesion. A 16-mer synthetic oligonucleotide containing a site-
specific cisplatin lesion, pGLuc4temGG-IS-Pt (5'-ACCTTCTG*G*CTCTTCC,
where the asterisks denote the platinated bases) and a 16-mer containing a
site-specific phenanthriplatin lesion, pGLuc8temG-IS-Pt (5'-
ACTCCTCG*TCTCTTCC), were prepared by Dr. Ga Young. The positions of
the modified sites in plasmids are shown in Figure 2.5.
PMI pGLuc4temGG
' -- A.-AAAG G GAA --
-- Ar-' r 7T , Mis-matched
Nt Bspol Nt.BspQi
pGLuc4temGG NH 3
~24b~ 'C(x 'r:T~:I'CI NH3
Naspol NBspoQ Cisplatin
BsmBI pGLuc8temG /
' -- AG CTGAGAAG;cAC-Ar' GAA;AGG(AAGAGGATC--
Nt.BbvCI Nt.BspQI N /NH 3
- Pt
Phenanthriplatinpromotor Pt region reporter gene poly(A)
Figure 2.5. DNA sequence of the platination regions in pGLuc4temGG and
pGLuc8temG vector; mismatched base pair and platination sites are
highlighted in the blue boxes.
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Two unique Nt.BbvCl restriction sites are 16 nucleotides away from each
other. The designed 16-mer synthetic oligonucleotide containing a site-
specific cisplatin-dGG lesion was inserted into the strand between the two
nicking restriction sites by the "gapping" strategy that we published
previously.21 Restriction analysis of unplatinated and platinated DNA strands
was carried out using PflMI. Platination of the DNA by cisplatin blocked
restriction digestion, showing that incorporation of cisplatin was successful.
Similar restriction enzyme digestions were carried out for all the DNA samples
either modified by platination or mismatched base pair, as shown in Figures
2.6-2.10.
1 2
Pt
'IT
Nt Bsp0i Nt Bsp~i
3086 bp 896 bp __
Figure 2.6. Agarose gel electrophoresis characterization of cisPt-4temGG
3982 bp. Lane 1: 1 kb DNA ladder;lane 2: cisPt-4temGG3982 bp after
incubation with restriction enzyme PflMI.
pGLuc4temGG
-- TCACCTC CTACA TCTC TAG S' 1.5 kb
N BspOI Nt BspOl 1 kb
1334 bp 896 bp
Figure 2.7. Agarose gel electrophoresis characterization of cisPt-4temGG
2230 bp. Lane 1: 1 kb DNA ladder; lane 2: cisPt-4temGG2230 bp after
incubation with restriction enzyme PflMI. The platination blocked the digestion
site so only one band was observed; lane 3: 4temGG2230 bp after incubation
with restriction enzyme PflMI.
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1 2 3
pGLuc8temG
BsmBI
5i' -- AG :GAGGAAGGACGAGAGG;AAAGiA T-- 3
AAC'
Nt BbvCI Nt Bspo
t1
3086 bp
kbA
896 bp
Figure 2.8. Agarose gel electrophoresis characterization of phenPt-8temG
3982 bp. Lane 1: 1 kb DNA ladder; lane 2: phenPt-8temG3982 bp after
incubation with restriction enzyme BsmBl; lane 3: 8temG3982 bp after
incubation with restriction enzyme BsmBl.
1 2 3
pGLuc8temG
NI-BbvCI NtBSpOI
1334 bp
2 kb -4
1.5 kb -
1 kb -
896 bp
Figure 2.9. Agarose gel electrophoresis characterization of phenPt-8temG
2230 bp. Lane 1: 1 kb DNA ladder; lane 2: phenPt-8temG2230 bp after
incubation with restriction enzyme BsmBl; lane 3: 8temG2230 bp after
incubation with restriction enzyme BsmBl.
1 2 3
NfMI
' AAGAG GATAAA AG GT
Nt BSPOI Nt BspOi
3086 bp
4 kb
3 kb
1 kb -
896 bp
Figure 2.10. Agarose gel electrophoresis characterization of mismatched
4temGG3982 bp. Lane 1: 1 kb DNA ladder; lane 2: Mismatched 4temGG3982
bp after incubation with restriction enzyme PfIMI; lane 3: 4temGG3982 bp
after incubation with restriction enzyme PfIMI.
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Atomic Force Microscopy Images. An aliquot of mismatched 3982 bp and
matched control short strands 2230 bp was imaged, and the results are
shown in Figure 2.11. An aliquot of cisplatin 4temGG 3982 bp matched
control short strands 2230 bp was imaged, and the results are shown in
Figure 2.12. An aliquot of phenanthriplatin 8temG 3982 bp matched control
short strands 2230 bp was imaged, and the results are shown in Figure 2.13.
Figure 2.11. AFM images of mismatched mixtures (mismatched-long strands
3982 bp with C:A mismatched and matched short strands 2230 bp DNA) with
0.6 [tM Endo Ill. The bright dots in the images are proteins.
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Figure 2.12. AFM images of mixture (cisplatin-long strands 3982 bp and
matched short strands 2230 bp) DNA with 0.6 [tM Endo 111. The last image
was zoomed in and it shows DNA strand bound with proteins.
Figure 2.13. Mixture (Phenanthriplatin-Long strands 3982 bp and Matched
Short Strands 2230 bp) DNA with 0.6 stM Endo 111.
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Examination of AFM images from our collaborator revealed a slight
redistribution of Endonuclease III onto strands that contain a cisplatin 1,2-GG
crosslink with a binding density ratio (longishort) of r = 1.23 ± 0.08. As a
control, we examined the redistribution of Endonuclease Ill in the presence of
mismatched 4temGG plasmid, where one guanine residue is replaced with an
A base to form a C:A mismatch. This phenanthriplatin inhibits transcription but
may evade repair machinery more than cisplatin. We observed that
Endonuclease Ill does not redistribute onto the phenanthriplatin 8temG 3982
bp, r=1.04 ± 0.06. The binding ratios of three samples were summarized in
Figure 2.14.
1.40
1.20
1.00
S0.80
0.60
0.40
0.20
0.00
Figure 2.14. Binding Density Ratios of mismatched DNA, cisplatin platinated
DNA and phenanthriplatin platinated DNA.
SUMMARY AND CONCLUSION
Eleven DNA strands were made, purified, characterized and summarized
in Table 2.1. The cisplatin platinated 3982 bp, cisplatin platinated 2230 bp,
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mismatched (C:A) 3982 bp, fully matched 3982 bp, 2230 bp, and 1752 bp
from 4temGG plasmid, phenanthriplatin platinated 3982 bp, phenanthriplatin
platinated 2230 bp, and fully matched 3982 bp, 2230 bp, and 1752 bp from
8temG plasmid. Both platinated DNA strands show higher binding density
ratios than mismatched ones, indicating that platination could block the DNA
mediated charge transport more effectively than mismatched base pairs.
Compared with cisplatin modification, phenanthriplatin had a lower binding
density ratio, which indicated that phenanthriplatin could evade the repair
proteins' detection and this could be a possible reason for why
phenanthriplatin showed a lower efficiency of nucleotide excision repair in
Chapter 1.
DNA Strands for AFM Studies
1. Cisplatin (platinated) long strand from plasmid insertion (3982 bp)
2. Cisplatin (platinated) short strand from plasmid insertion (2230 bp)
3. Mismatched (C:A) long strand from plasmid insertion (3982 bp)
4. Long strand fully matched from plasmid insertion (3982 bp GG)
5. Short strands from plasmid restriction GG (2230 bp)
6. Short strands from plasmid restriction GG (1752 bp)
7. Phenanthriplatin (platinated) long strand from plasmid insertion (3982 bp)
8. Phenanthriplatin (platinated) short strand from plasmid insertion (2230 bp)
9. Long strand fully matched from plasmid insertion (3982 bp G)
10. Short strands from plasmid restriction G (2230 bp)
11. Short strands from plasmid restriction G (1752 bp)
Table 2.1. All the DNA strands prepared for AFM studies.
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